View ValuationVitalist 将来の成長Future 基準チェック /06現在、 Vitalistの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Consumer Durables 収益成長8.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canadaお知らせ • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.お知らせ • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.お知らせ • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.お知らせ • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.お知らせ • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vitalist は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:VTLS.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255-4-2-2N/A9/30/20256-3-4-4N/A6/30/20255-4-4-4N/A3/31/20255-4-2-2N/A12/31/20245-3-2-2N/A9/30/20244-4-2-2N/A6/30/20242-5-3-3N/A3/31/202424-4-4N/A12/31/20233-12-4-4N/A9/30/20234-17-5-5N/A6/30/20236-17-6-6N/A3/31/20238-28-7-7N/A12/31/202210-14-9-9N/A9/30/20229-10-8-8N/A6/30/20229-10-9-9N/A3/31/20227-10-13-13N/A12/31/20215-10-12-12N/A9/30/20217-12-11-11N/A6/30/20218-14-9-9N/A3/31/20219-14-5-5N/A12/31/202010-15-3-3N/A9/30/20209-14-8-7N/A6/30/20208-11-8-7N/A3/31/20207-10-9-8N/A3/31/20193-3N/A-2N/A3/31/20181-1N/A0N/A3/31/201720N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VTLS.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VTLS.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VTLS.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VTLS.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VTLS.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VTLS.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-durables 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 16:12終値2026/07/23 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vitalist Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 20Vitalist Inc., Annual General Meeting, Sep 29, 2026Vitalist Inc., Annual General Meeting, Sep 29, 2026. Location: at 2100 livingston place, 222 3 ave sw, ab t2p 0b4, calgary Canada
お知らせ • Jul 02Vitalist Inc. Announces Resignation of Nick Padula from Chief Revenue Officer RoleVitalist Inc. announced that Chief Revenue Officer Nick Padula would be concluding his role with the Company following his support of the post-acquisition integration and commercial transition of Somatix Inc. Nick and the Vitalist team were working closely together to ensure a seamless hand-off of responsibilities over the coming weeks. In connection with Mr. Padula's departure, Vitalist's commercial and sales operations would report directly to CEO Kalvie Legat with health and wellness business development continuing to report through Dr. Charles Herman who serves as CSO of Vitalist and CEO of Vitalist subsidiary Somatix Inc.
お知らせ • May 01Vitalist Inc. (TSXV:VITA) acquired Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing. Vitalist Inc. (TSXV:VITA) completed the acquisition of Somatix, Inc. on April 30, 2026. Under the terms of the transaction, Vitalist issued 15,581,854 of its common shares in exchange for 100% of the common stock of Somatix. Following closing, the former Somatix stockholders held approximately 23.24% of the issued and outstanding common shares of Vitalist. Kingswood Capital Partners, LLC was paid a financial advisory fee consisting of CAD 0.13 million ($0.1 million) in cash and 87,812 common shares of Vitalist issued at a price of CAD 0.71 per share.
お知らせ • Apr 02Vitalist Inc. Announces Executive AppointmentsVitalist Inc. announced that Dr. Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix. Dr. Herman is a distinguished surgeon and healthcare executive with over 20 years of experience in clinical practice and medical technology innovation. In addition to his leadership at Somatix, Dr. Herman serves as a Portfolio Manager at Forefront Analytics, where he applies quantitative insights to healthcare investments. He previously served as Chief Medical Executive for multiple healthcare systems and has held executive leadership and faculty positions at major medical institutions and universities. Dr. Herman holds an M.D. from Albany Medical College in New York and an M.B.A. from the Wharton School of the University of Pennsylvania, where he is a Palmer Scholar. Nick Padula joins the executive team as Chief Revenue Officer of Vitalist. Mr. Padula is a senior executive with over 30 years of experience driving market share growth and operational excellence across major healthcare and medical technology firms. He has previously held senior leadership roles at Philips Healthcare, GE Healthcare, and Health Recovery Solutions, where he led large-scale commercial organizations and successfully integrated complex global acquisitions.
お知らせ • Apr 01Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million.Vitalist Inc. (TSXV:VITA) entered into a definitive merger agreement to acquire Somatix, Inc. for CAD 6.7 million on March 30, 2026. The consideration consists of 15.58 million common equity of Vitalist Inc. to be issued for common equity of Somatix, Inc. Following the Closing, Somatix, Inc's Stockholders will hold approximately 23.4% of Vitalist's issued and outstanding common shares. Upon closing of the Transaction, Charles Herman will be appointed as Chief Science Officer of Vitalist and will continue to serve as CEO of Somatix and Nick Padula joins the executive team as President of Somatix and Chief Revenue Officer of both Somatix and Vitalist. For the period ending December 31, 2025, Somatix, Inc. reported total revenue of CAD 0.15 million ($0.11 million) and net loss of CAD 4.25 million ($3.05 million). As of December 31, 2025, Somatix, Inc. reported total assets of CAD 3.24 million ($2.33 million). Completion remains subject to the final approval of TSX Venture Exchange and the satisfaction of customary closing conditions. Kingswood Capital Partners, LLC acted as financial advisor for Somatix, Inc. Kier Advisory Services acted as financial advisor for Vitalist Inc. Kingswood Capital Partners, LLC will receive a finder’s fee consisting of CAD 0.14 million ($0.1 million) in cash and Vitalist common shares equivalent to a value of CAD 0.06 million ($0.05 million), conditional upon the Closing.
お知らせ • Dec 02Vitalist Inc. and MicroEJ Announce New Reebok Smartwatch Powered by VitalOSVitalist Inc. and MicroEJ announced the launch of the first Reebok smartwatch powered by VitalOS, marking the public debut of an operating system designed to support consumer brands entering the wearable market. With Reebok as the first commercial implementation, VitalOS illustrates the platform's capabilities and showcases its capabilities, providing an alternative approach to developing wearables without reliance on proprietary ecosystems. VitalOS is built on MicroEJ's proven virtualization technology, MicroEJ VEE, and its wearable solution, VEE Wear -- part of a platform that already powers more than 400 million connected devices worldwide. Together, the companies have created a foundation that streamlines the cost, speed, and scale of wearable development: Low-power architecture designed to support extended battery performance; 6-9 month development cycles; Customization options for brand-specific experiences; Hardware-agnostic scalability.